LUMBERTON HOSPITAL LLC
1. Target Overview & Investment Thesis
LUMBERTON HOSPITAL LLC is a 4-bed community hospital in nan, TX with $13.0M in net patient revenue and a 2.5% operating margin. The hospital serves a payer mix of 0.0% Medicare, 0.0% Medicaid, and 100.0% commercial.
Thesis: Turnaround. Our ML models identify $959K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 2.5% to 9.9% (+738bps).
| Net Revenue HCRIS | $13.0M |
| Current EBITDA COMPUTED | $322K |
| Operating Margin COMPUTED | 2.5% |
| Occupancy HCRIS | 13.7% |
| Revenue / Bed COMPUTED | $3.2M |
| Net-to-Gross HCRIS | 100.0% |
| Distress Probability ML | nan% |
2. Market Context & Competitive Position
TX has 583 Medicare-certified hospitals with a median operating margin of -0.7%. The target's margin of 2.5% places it above the state median. Among 0 size-comparable peers (2-8 beds), the median margin is 0.0%. The target performs in line with or above peers.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (2-8), prioritizing same-state peers. 0 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| LUMBERTON HOSPITAL LLC (Target) | TX | 4 | $13.0M | 2.5% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $959K (738bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $273K | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $260K | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $258K | +199bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $158K | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $10K | +7bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $322K |
| + RCM Uplift | +$959K |
| Pro Forma EBITDA | $1.3M |
| Current Margin | 2.5% |
| Pro Forma Margin | 9.9% |
| WC Released (1x) | $498K |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $495K | $11.7M | 23.65x | 88.3% |
| Base (11x exit) | 10.0x | 11.0x | $495K | $13.0M | 26.34x | 92.4% |
| Bull Case | 9.0x | 11.0x | $446K | $16.4M | 36.73x | 105.6% |
| Bull (12x exit) | 9.0x | 12.0x | $446K | $18.0M | 40.36x | 109.5% |
| Bear Case | 11.0x | 10.0x | $545K | $6.8M | 12.40x | 65.5% |
| Bear (11x exit) | 11.0x | 11.0x | $545K | $7.6M | 13.97x | 69.5% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| Medium | Low occupancy | At 13.7%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 0 hospitals with 2-8 beds
- Same-state prioritization (n=13)
- Comp margins: P25=nan% / P50=0.0% / P75=nan%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.